Radiopharm Theranostics Limited (RADX)
RADX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$1.20
+8.10% on the day
Market cap
$17.3M
Nano cap
Revenue · 2025
$3.6M
No prior year to compare
Net income · 2025
-$38.3M
-1055.3% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), period ending 2025-06-30, https://www.sec.gov/Archives/edgar/data/1949257/000121390025088699/0001213900-25-088699-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), period ending 2025-06-30.
Profile
| Field | Value |
|---|---|
| Ticker | RADX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Australia |
| IPO year | Not reported by the screener |
| SEC CIK | 0001949257 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | C3 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $3.6M |
| Net income | -$38.3M |
| Operating income | Not in SEC XBRL data |
| Net margin | -1055.3% |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | Not in SEC XBRL data |
| Total assets | Not in SEC XBRL data |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 4.8× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS | 424B3 | 2026-09-23 |
| Latest annual report ANNUAL REPORT | 20-F | 2026-09-30 |
| Latest quarterly / interim REPORT OF FOREIGN PRIVATE ISSUER | 6-K | 2026-10-05 |
Source: SEC EDGAR submissions feed, 156 recent filings. All filings on EDGAR.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| AKTX | Akari Therapeutics plc ADS | $7.90 | -7.49% | $18.1M |
| NEUP | Neuphoria Therapeutics Inc. | $3.39 | +2.11% | $18.3M |
| NCEL | NewcelX Ltd. | $2.84 | -2.20% | $16.4M |
| MRKR | Marker Therapeutics Inc. | $0.9249 | -8.43% | $15.4M |
| QNRX | Quoin Pharmaceuticals Ltd. | $4.15 | -4.82% | $19.9M |
| OPTH | Optimi Health Corp. Common Shares | $3.50 | -3.58% | $20.0M |
| DARE | Dare Bioscience Inc. | $0.7477 | -0.32% | $14.7M |
| PTN | Palatin Technologies Inc. | $8.19 | -4.21% | $14.6M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier